Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Doxorubicin (Adriamycin) 是一种有细胞毒性的蒽环类抗生素,具有肿瘤化疗作用。它抑制DNA 拓扑异构酶 I 和拓扑异构酶 II,IC50分别为0.8 μM 和2.67 μM,从而抑制 DNA 复制。它下调AMPK 的基础磷酸化以及下游 acetyl-CoA 羧化酶。它诱导凋亡和自噬 。 在相同实验条件下,摩尔浓度相同的化合物盐形式与游离态具有相同的生物活性,但盐形式 Doxorubicin hydrochloride 的水溶性和稳定性通常比游离态更好。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | 待询 | 待询 | ||
50 mg | 待询 | 待询 | ||
500 mg | 待询 | 待询 |
Doxorubicin 的其他形式现货产品:
产品描述 | Doxorubicin (Adriamycin) is a Topoisomerase II (Top2) inhibitor with antineoplastic activity. |
靶点活性 | Topoisomerase I:0.8 μM (IC50), Topoisomerase II:2.67 μM (IC50) |
体外活性 | The combination of Doxorubicin and Simvastatin at the highest tested concentrations (2 μM and 10 μM, respec-tively) kills 97% of the Hela cells[2]. |
体内活性 | Mice bearing PC3 xenografts are injected with 2, 4 or 8 mg/kg Doxorubicin and tumor volume is measured over time. A dose of 2 mg/kg does not affect tumor growth while higher dosages delay tumor growth initially (p<0.05 at days 18 and 22), 4 mg/kg or 8 mg/kg Doxorubicin significantly reduces levels of c-FLIP in PC3 xenografts[3]. In rats, a single intraperitoneal injection of 10 mg/kg (Doxorubicin 1), 10 daily intraperitoneal injections of 1 mg/kg (Doxorubicin 2), or in 5 weekly intraperitoneal injections of 2 mg/kg (Doxorubicin 3). An 80% mortality rate is observed at day 28 in Doxorubicin 1, while Doxorubicin 2 and Doxorubicin 3 reached 80% mortality on days 107 and 98, respectively. Fractional shortening decreased by 30% at week 2 in Doxorubicin DOX1, 55% at week 13 in Doxorubicin 2, and 42% at week 13 in Doxorubicin 3[4]. |
细胞实验 | Doxorubicin is dissolved in stock solutions (1 mM) and serially diluted with RPMI 1640 media (0.1, 1, and 2 μM)[2]. 160 μL of Hela cells suspension (3×104 cell/mL) is dispensed into three 96-well U-bottom microplates and incubated for 24 h at 37°C in a fully humidified atmosphere of 5% CO2. In plate 1, serial dilutions of Doxorubicin (20 μL; final concentration, 0.1-2 μM) and Simvastatin (20 μL; final concentration, 0.25-2 μM) are added to a final volume of 200 μL and incubated for another 72 h. In plates 2 and 3 serial dilutions of each drug (Simvastatin or Doxorubicin, 40 μL) are added. After an incubation period of 24 h, the medium is aspirated and the cells are washed in PBS. Then, serial dilutions of other drug (40 μL) are added and supplemented with culture medium to a final volume of 200 μL, and incubated for 48 h. Doxorubicin and Simvastatin are used individually as positive controls (40 μL in each well), and the cells treated only with solvent are considered as negative controls. To evaluate cell survival, 20 μL of MTT solution (5 mg/mL in PBS) is added to each well and incubated for 3 h. Then the media is replaced with 150 μL of DMSO, and complete solubilization of formazan crystals is achieved by repeated pipetting of the solution. Absorbance is then determined at 540 nm by an ELISA plate reader. Each drug concentration is assayed in 4 or 8 wells and repeated 3 times. The cytotoxic/cytostatic effect of Doxorubicin is expressed as the relative viability (% control) and calculated. Percentage of cell survival in the negative control is assumed as 100. Relative viability=(experimental absorbance-background absorbance)/ (absorbance of untreated controls-background absorbance)×100 %[2]. |
别名 | Hydroxydaunorubicin, 阿霉素, Adriamycin |
分子量 | 543.52 |
分子式 | C27H29NO11 |
CAS No. | 23214-92-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50mg/mL
DMSO: 10 mM
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8399 mL | 9.1993 mL | 18.3986 mL | 45.9965 mL |
5 mM | 0.368 mL | 1.8399 mL | 3.6797 mL | 9.1993 mL | |
10 mM | 0.184 mL | 0.9199 mL | 1.8399 mL | 4.5996 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Doxorubicin 23214-92-8 Chromatin/Epigenetic DNA Damage/DNA Repair PI3K/Akt/mTOR signaling Topoisomerase AMPK HIV Bacterial Hydroxydaunorubicin inhibit Antibiotic ADC Payload HBV Inhibitor AMP-activated protein kinase Hepatitis B virus Apoptosis 阿霉素 Mitophagy Adriamycin Mitochondrial Autophagy Human immunodeficiency virus Autophagy ADC Cytotoxin inhibitor